A novel HEAT repeat protein 5B anaplastic lymphoma kinase fusion in lung adenocarcinoma confers sensitivity… | ScholarDeck

Paper

A novel HEAT repeat protein 5B anaplastic lymphoma kinase fusion in lung adenocarcinoma confers sensitivity to ensartinib.

New research · Pathology

Anti-cancer drugs · 2w

Case reportAnti-cancer drugs· Aug 2026

A novel HEAT repeat protein 5B anaplastic lymphoma kinase fusion in lung adenocarcinoma confers sensitivity to ensartinib.

Guangyi Zhang, Di Wu, Haitao Deng … Huiyun Peng

Read paper

Molecular PathologyCase reportTreatmentQ3IF 2.0

HEATR5B-anaplastic lymphoma kinase fusion lung adenocarcinoma showed durable response to ensartinib

A novel HEAT repeat protein 5B anaplastic lymphoma kinase fusion in lung adenocarcinoma confers sensitivity to ensartinib.

Guangyi Zhang … Huiyun Peng

Anti-cancer drugs · Aug 2026

Background

Anaplastic lymphoma kinase (anaplastic lymphoma kinase) rearrangements are rare but highly actionable drivers in non-small cell lung cancer; however, uncommon fusion variants lack standard management.

Results

24+ months

response held with no cancer progression, and ongoing

More results

We report the clinical outcome of a novel HEAT repeat protein 5B (HEATR5B)-anaplastic lymphoma kinase fusion treated with ensartinib.

A 52-year-old Chinese woman with stage IVA lung adenocarcinoma and left adrenal metastasis underwent tumor biopsy.

Targeted DNA-based next-generation sequencing (next-generation sequencing) identified HEATR5B(END..

More results

No grade greater than or equal to 3 adverse events were observed; preexisting weight loss ceased.

“

Conclusion

Comprehensive next-generation sequencing and anaplastic lymphoma kinase immunohistochemistry are essential for detecting rare actionable anaplastic lymphoma kinase variants.

Read paper